ImmunityBio reported FY 2025 net product revenue of USD 113 million, up about 700% year-over-year, with Q4 2025 net product revenue of USD 38.3 million (+431%). FY 2025 net loss attributable to common stockholders was USD 351.4 million, compared with a Q4 net loss attributable to common stockholders of USD 61.9 million. For FY 2025, R&D expense was USD 218.6 million and SG&A expense was USD 150 million; in Q4, R&D expense was USD 63.9 million and SG&A expense was USD 38.7 million. Cash, cash equivalents and marketable securities totaled USD 242.82 million at Dec. 31, 2025. The company said ANKTIVA unit sales volume rose about 750% in 2025 versus 2024 to 3,745 units and net product revenue increased 20% quarter-over-quarter. ImmunityBio highlighted expanded global authorizations for ANKTIVA plus BCG in BCG-unresponsive NMIBC CIS across the U.S., U.K., EU and Saudi Arabia (33 countries total), and noted the first approval for lung cancer: Saudi Arabia’s SFDA granted conditional accelerated approval in January 2026 for ANKTIVA with checkpoint inhibitors in metastatic NSCLC, with a commercial launch planned within 60 days. The company also cited distribution and commercialization partnerships with Accord Healthcare in Europe and BioPharma & Cigalah in Saudi Arabia, and reiterated plans for additional regulatory submissions in 2026 and a BLA filing targeted by Q4 2026 for its BCG-naïve bladder cancer randomized trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602230700BIZWIRE_USPR_____20260223_BW889360) on February 23, 2026, and is solely responsible for the information contained therein.